Zeo ScientifiX Faces Critical Going Concern Doubts Despite Revenue Growth

Biotech firm Zeo ScientifiX warns it may not survive the year due to a severe cash crunch and negative equity, despite posting strong revenue growth and high margins.

The biotechnology firm Zeo ScientifiX is confronting a severe financial crisis that threatens its very existence, according to its latest quarterly report. Management has expressed significant doubt about the company's ability to continue as a going concern over the next twelve months. This stark warning comes despite the company posting a double-digit revenue increase for the period, highlighting a troubling disconnect between its operational performance and its precarious balance sheet.

A Deepening Financial Strain

For the quarter ended January 31, 2026, Zeo ScientifiX reported revenue of $1.446 million, representing a 32.7% year-over-year gain. This growth was primarily driven by sales of aesthetic biologics and its Patient Pure X™ (PPX™) service platform. The company also maintained a robust gross margin exceeding 80% and reduced its net loss to $852,000.

However, these operational improvements are overshadowed by a dire financial position. The company's operational cash flow remained deeply negative at -$471,000. The balance sheet reveals a critical imbalance: total assets of approximately $2.6 million are outweighed by liabilities nearing $3 million. This structure leaves Zeo ScientifiX heavily reliant on continuous capital infusions simply to maintain operations. The need for cash was immediately demonstrated in February 2026, when the company was required to secure an additional $650,000 through a private placement.

Regulatory Headwinds Compound Capital Crisis

The path forward is further complicated by significant regulatory uncertainties, which the company cites as a major burden. These external pressures, combined with the persistent high demand for capital, are creating what management describes as an unsustainable strain on its financial statements. The going concern warning underscores that without securing substantial and ongoing financing, the company's future is in jeopardy, regardless of its top-line sales momentum.